Mukka Proteins to acquire 1,000 shares of EPPL for ₹32.30 Lakhs, making it wholly-owned subsidiary
Mukka Proteins will acquire 1,000 shares of its subsidiary EPPL for ₹32.30 Lakhs. This will make EPPL a wholly-owned subsidiary, increasing Mukka's stake from 74.01% to 100%. The deal is part of strategic expansion in Alternate Proteins business and is expected to complete by June 30, 2026.
The acquisition is a strategic move to consolidate a subsidiary and expand a business vertical. While positive, the financial impact is currently limited by the acquisition value and the subsidiary's current financials.
The acquisition is strategic, aimed at expanding the company's business and making a subsidiary wholly-owned, which is generally viewed positively.
Mukka Proteins Limited announced today, February 12, 2026, that its Board of Directors has approved the acquisition of 1,000 equity shares of its subsidiary, Ento Proteins Private Limited (EPPL). The face value of each share is ₹100, and the total consideration for this acquisition is ₹32,30,000 (Rupees Thirty-Two Lakhs Thirty Thousand only).
This acquisition is part of the company's strategic investment plans to expand its Alternate Proteins business. Upon completion, EPPL will become a wholly-owned subsidiary of Mukka Proteins Limited, increasing the company's shareholding in EPPL from the current 74.01% to 100%.
EPPL, incorporated on March 8, 2021, is a manufacturer of insect meal and insect oil. For the financial year 2024-25, EPPL reported a turnover of ₹7,46,27,305 and a Profit After Tax (PAT) of ₹49,47,474. The acquisition is expected to be completed by June 30, 2026. The board meeting where this decision was made commenced at 4:00 p.m. and concluded at 4:45 p.m.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.